OncoSil Medical Ltd is a publicly traded medical device company (ASX: OSL) with a global footprint.
OncoSil™ is our brachytherapy device, which delivers a targeted intratumoural placement of Phosphorous-32 (32P) in the treatment of locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy.
Led by CEO and Managing Director Nigel Lange, OncoSil Medical operates in a number of markets across Europe and Asia Pacific and is headquartered in Sydney, Australia.
It has taken many committed individuals 15 years of dedication to get us to where
we are today.
First commercial pancreatic cancer treatment with the OncoSil™ device in Spain.
The PanCO Study is published in ESMO Open1
OncoSil™ System receives regulatory approval in Hong Kong.
OncoSil™ System receives regulatory approval in Switzerland.
OncoSil™ System receives regulatory approval from Singapore’s Health Sciences Agency
OncoSil™ System receives regulatory approval in New Zealand.
OncoSil™ system receives regulatory approval from Malaysia’s Medical Device Authority. Registered under Act 737. Registration Number: GD2812320-46044.
British Standards Institute (BSI) grants European CE marking for the OncoSil™ System and designates OncoSil™ a breakthrough device for the treatment of locally advanced pancreatic cancer in combination with chemotherapy2
FDA grants Breakthrough Device Designation for the OncoSil™ device for treatment of unresectable locally advanced pancreatic cancer in combination with chemotherapy.
PANCO study recruitment completed
First US study participant implanted with the OncoSil™ device as part of the OncoPaC-1 study3
First study participant implanted with the OncoSil™ device as part of the global PanCO study1
OncoSil Medical receives investigational device exemption (IDE) approval from the FDA to conduct a clinical study
Enigma Therapeutics Ltd is acquired by Neurodiscovery Ltd Neurodiscovery Ltd changes its name to OncoSil Medical Ltd and focuses on the development of OncoSil™
pSivida Corp grants an exclusive worldwide royalty-bearing license agreement with Enigma Therapeutics Ltd for the development of BrachySil™
2004 to 2009
Early clinical development phases for the OncoSil™ technology
The OncoSil™ technology is developed as BrachySil™ by pSivida Corp
Ross PJ, Wasan HS, Croagh D et al. Results of a Single-Arm Pilot Study of 32P Microparticles in Unresectable Locally Advanced Pancreatic Adenocarcinoma with Gemcitabine/Nab-Paclitaxel or FOLFIRINOX Chemotherapy. ESMO Open February 2022; 7 (1): 100356.
OncoSil™ is intended for intratumoural implantation into a pancreatic tumour via injection under endoscopic ultrasound guidance. OncoSil™ is indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy.
OncoPaC-1 ClinicalTrials.gov Identifier: NCT03076216